|
|
|
|
|
|
by kdps
1980 days ago
|
|
|
That's what BioNTech has been researching for years. BNT162b2 is, slightly exaggerated, a by-product. From https://en.wikipedia.org/wiki/BioNTech: It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. |
|
|